MA-ROSLINCT
RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, FRCPE, FMedSci, FRSE, FRSA and Alexander Vos as new Non-Executive Directors.
Professor Sir Peter Mathieson brings an exceptional wealth of experience in higher education, medical research, and organisational leadership. Currently serving as the Principal of the University of Edinburgh since 2018, Sir Peter also holds Honorary Professorships in Medicine at the Universities of Edinburgh, Hong Kong, and Bristol. His illustrious career includes notable roles such as President of the University of Hong Kong (2014-18) and Dean of the Faculty of Medicine & Dentistry at the University of Bristol (2008-14). Sir Peter was knighted in the 2023 New Year Honours for his services to higher education, reflecting his significant contributions to the field. Additionally, Sir Peter has held numerous non-executive and trustee roles, including positions with the Renal Association, Council for the Advancement and Support of Education (CASE), Scottish Funding Council, and Newbattle Abbey College Trust. His career highlights also include tenure as an honorary consultant nephrologist with a clinical interest in autoimmune diseases and renal transplantation. He has led a significant research group in Bristol and contributed extensively to medical education and clinical research, particularly in Africa. His publication record includes 327 works, covering clinical trials, laboratory research, and societal matters, and he has been a driving force in academic careers both in the UK and internationally.
Alexander Vos is a biotech leader with 30 years of experience, specializing in biopharmaceuticals and cell & gene therapy. He started at McKinsey & Co. and held executive roles at Genzyme Therapeutics Europe. He was CEO of MediService AG, PAION AG's Deputy-CEO and COO, and led PharmaCell BV to a successful sale to Lonza. Vos also served as CEO of VarmX and VectorY, setting strategy and raising significant funds for these companies. Currently, he sits on several biotech boards and is a Venture Partner at BioGeneration Ventures. He holds an MS in Pharmacy and Pharmacology and an MBA from Stanford University. Alexander Vos's proven leadership in advancing innovative therapies and achieving successful exits for investors will be invaluable to RoslinCT. His skills in biotech strategy development, operations, and M&A will complement the existing strengths of the board.
"We are excited to welcome both Professor Sir Peter Mathieson and Alexander Vos to our Board," said Geoffrey Hamilton Fairley, Executive Chairman of the RoslinCT Group. "Sir Peter's extensive experience in academic leadership and his proven track record in advancing medical research and education, combined with Alexander's strategic insight and wealth of experience in biotech and cell and gene therapy, align perfectly with RoslinCT's mission. Their combined expertise will be instrumental as we continue to develop and manufacture cutting-edge cell and gene therapies."
"I am honoured to join RoslinCT at such an exciting time for the company and the field of cell and gene therapy," said Sir Peter Mathieson. "I look forward to contributing to RoslinCT's innovative efforts to bring life-saving therapies to patients worldwide."
Alexander Vos added, "I am excited to be part of RoslinCT's journey and to support its mission to advance cell and gene therapies. The company is at the forefront of groundbreaking science, and I am eager to contribute to its continued success."
About RoslinCT
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the ground-breaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones. These include being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with the partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialisation.
Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialisation and deliver life-saving Cell and Gene Therapies worldwide. RoslinCT is a GHO Capital portfolio company. Discover more about our services at www.roslinct.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625300790/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IDC MarketScape Positions TreviPay as a Major Player in Worldwide Accounts Receivable Automation Applications for the Enterprise4.12.2024 14:00:00 CET | Press release
TreviPay, the most-trusted B2B payments and invoicing network, today announced it has been named a Major Player in the IDC MarketScape: Worldwide Accounts Receivable Automation Applications for the Enterprise 2024 Vendor Assessment1. TreviPay was one of the 14 vendors with a SaaS or cloud offering to be evaluated for their accounts receivable (A/R) strategy and capabilities. The IDC MarketScape report highlighted a selection of TreviPay’s strengths including: Robust APIs: “The TreviPay suite of APIs enables merchants to directly integrate invoicing into any ecommerce platform, point-of-sale environment, or order management platform. In addition, TreviPay enables a white-labeled solution that may be embedded within the checkout, giving buyers a line of sight into how much credit they have available in real time. Terms to buyer and settlement with client are both independently configurable, enabling guaranteed DSO.” Expanding/Expansive Ecosystem: “The most recent investments include a st
New Research from NetApp Finds One in Five Companies Unable to Recover Data After Cyberattack4.12.2024 14:00:00 CET | Press release
Survey of cybersecurity leaders highlights the importance of data classification in enhancing cyber resilience NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the release of its latest report analyzing the state of cybersecurity and offering actionable insights to help organizations strengthen their cyber resiliency. The Futurum Group study, "Cloud, Complexity, AI: The Triple Threat Demanding New Cyber Resilience Strategies" sponsored by NetApp, provides a comprehensive analysis of evolving cyber threats and resiliency strategies. The study, which surveyed over 1,300 cybersecurity leaders across industries worldwide, reveals that more than 54 percent of organizations experienced a cyberattack in the past 12 to 18 months, with one in five unable to recover lost data. The report highlights the urgent need for enterprises to leverage intelligent data infrastructure to address growing risks posed by sophisticated threats, operational complexity, and the
Curtiss-Wright and Sintavia Deliver First Submarine Component Utilizing an Additively Manufactured Impeller to be Installed in a U.S. Navy Vessel4.12.2024 13:59:00 CET | Press release
Curtiss-Wright’s EMS Division today announced that it has delivered the first submarine component with an additively manufactured (AM) impeller that will be installed in a U.S. Navy vessel. Curtiss-Wright’s Engineered Pump Division (EPD) in Bethlehem, PA, Bechtel Plant Machinery Inc. (BPMI) in Monroeville, PA, and Sintavia, LLC in Fort Lauderdale, FL, collaborated to develop, manufacture, test, and supply the first submarine component utilizing a qualified, metal additively manufactured part. Sintavia, a leader in designing and manufacturing critical additively manufactured defense components, provided the AM impeller after a thorough qualification process. This impeller was assembled into the pump and tested at Curtiss-Wright’s facility in Bethlehem, PA. Additive manufacturing technology offers a solution to the development of a product or component that historically has been difficult or costly to manufacture, often resulting in delays. The use of this technology is expected to provi
LR Health & Beauty Records Strong Sales Growth of 7.2%4.12.2024 13:43:00 CET | Press release
The social commerce company in the food supplements and cosmetics sector presents report for Q3 2024 LR Health & Beauty – the leading digital social commerce company in Europe – has published its quarterly report for Q3 2024 and was able to announce a confirmation of the growth trend. The company, which specializes in nutritional supplements and cosmetic products, increased its sales significantly by 7.2% to EUR 69.4 million in the third quarter. The high demand for the new decorative cosmetics line LR ZEITGARD Signature and the large influx of new sales partners thanks to the realignment of the career plan were the primary contributors to this result. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204411818/en/ The company headquarters of LR Health & Beauty in Ahlen, Germany. (Photo: Business Wire) Launch of decorative cosmetics line supports growth trend In October, LR Health & Beauty expanded its product range to inclu
LabVantage Solutions and The Netherlands Forensic Institute (NFI) Partner to Advance Digital Transformation in Forensic Science4.12.2024 13:30:00 CET | Press release
—New Collaboration Enhances NFI’s IT Infrastructure with Advanced LIMS to Streamline Workflows, Improve Data Integrity, and Optimize Forensic Operations— LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS platforms enabling rapid deployment at reduced costs, and The Netherlands Forensic Institute (NFI) today jointly announced a partnership to digitalize forensic laboratory workflows as part of NFI’s IT renewal initiative. A key aspect of this collaboration is the implementation of LabVantage Solutions’ Laboratory Information Management System (LIMS), which is designed to streamline NFI’s forensic operations by replacing fragmented processes and incorporating advanced capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204274659/en/ (Graphic: Business Wire) NFI’s IT renewal initiative aims to modernize its infrastructure by replacing outd
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom